company background image
ALT

Altimmune NasdaqGM:ALT Stock Report

Last Price

US$17.36

Market Cap

US$842.0m

7D

40.0%

1Y

44.4%

Updated

14 Aug, 2022

Data

Company Financials +
ALT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ALT Stock Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

Altimmune Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Altimmune
Historical stock prices
Current Share PriceUS$17.36
52 Week HighUS$18.55
52 Week LowUS$3.83
Beta0.47
1 Month Change53.22%
3 Month Change260.92%
1 Year Change44.43%
3 Year Change755.17%
5 Year Change-71.77%
Change since IPO-92.68%

Recent News & Updates

Aug 10

Altimmune Q2 2022 Earnings Preview

Altimmune (NASDAQ:ALT) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.48 (+20.0% Y/Y) and the consensus Revenue Estimate is $0.75M (+435.7% Y/Y). Over the last 3 months, EPS estimates have seen 5 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Jun 29

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data. It is estimated that the global NASH market could be worth $20 billion by 2027. Interim results from the phase 2 MOMENTUM study using pemvidutide for obesity are expected in Q4 of 2022; This will deal with 24-week interim data for weight loss. The global obesity treatment market will reach $15.6 billion by 2024.

Shareholder Returns

ALTUS BiotechsUS Market
7D40.0%1.2%3.2%
1Y44.4%-21.7%-10.2%

Return vs Industry: ALT exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: ALT exceeded the US Market which returned -10.2% over the past year.

Price Volatility

Is ALT's price volatile compared to industry and market?
ALT volatility
ALT Average Weekly Movement16.7%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: ALT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: ALT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199747Vipin Garghttps://altimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

Altimmune Fundamentals Summary

How do Altimmune's earnings and revenue compare to its market cap?
ALT fundamental statistics
Market CapUS$841.99m
Earnings (TTM)-US$96.94m
Revenue (TTM)US$3.48m

242.3x

P/S Ratio

-8.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALT income statement (TTM)
RevenueUS$3.48m
Cost of RevenueUS$81.24m
Gross Profit-US$77.76m
Other ExpensesUS$19.17m
Earnings-US$96.94m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.00
Gross Margin-2,237.55%
Net Profit Margin-2,789.26%
Debt/Equity Ratio0%

How did ALT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ALT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALT?

Other financial metrics that can be useful for relative valuation.

ALT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue189.5x
Enterprise Value/EBITDA-7.1x
PEG Ration/a

Price to Book Ratio vs Peers

How does ALT's PB Ratio compare to its peers?

ALT PB Ratio vs Peers
The above table shows the PB ratio for ALT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.8x
INO Inovio Pharmaceuticals
2.2x41.8%US$655.9m
NKTX Nkarta
2x-11.1%US$840.8m
ACLX Arcellx
3.7x3.6%US$811.9m
NUVL Nuvalent
3.2x-17.9%US$811.4m
ALT Altimmune
4.3x-14.8%US$842.0m

Price-To-Book vs Peers: ALT is expensive based on its Price-To-Book Ratio (4.3x) compared to the peer average (2.8x).


Price to Earnings Ratio vs Industry

How does ALT's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: ALT is expensive based on its Price-To-Book Ratio (4.3x) compared to the US Biotechs industry average (1.9x)


Price to Book Ratio vs Fair Ratio

What is ALT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALT's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ALT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-14.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALT's revenue (99.5% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: ALT's revenue (99.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Altimmune performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-21.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALT is currently unprofitable.

Growing Profit Margin: ALT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.

Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: ALT has a negative Return on Equity (-49.83%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Altimmune's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALT's short term assets ($195.5M) exceed its short term liabilities ($13.8M).

Long Term Liabilities: ALT's short term assets ($195.5M) exceed its long term liabilities ($1.5M).


Debt to Equity History and Analysis

Debt Level: ALT is debt free.

Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 0.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALT has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 43% each year.


Discover healthy companies

Dividend

What is Altimmune current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Vipin Garg (64 yo)

3.75yrs

Tenure

US$2,631,639

Compensation

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...


CEO Compensation Analysis

Compensation vs Market: Vipin's total compensation ($USD2.63M) is below average for companies of similar size in the US market ($USD3.86M).

Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ALT's management team is considered experienced (3.9 years average tenure).


Board Members

Experienced Board: ALT's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ALT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.5%.


Top Shareholders

Company Information

Altimmune, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Altimmune, Inc.
  • Ticker: ALT
  • Exchange: NasdaqGM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$841.988m
  • Shares outstanding: 48.50m
  • Website: https://altimmune.com

Number of Employees


Location

  • Altimmune, Inc.
  • 910 Clopper Road
  • Suite 201S
  • Gaithersburg
  • Maryland
  • 20878
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/14 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.